April 2025:
GLX-100 Phase 1b Results to Be Presented at American Urological Association April 26, 2025

Clinical results from Glycologix’ Phase Ib trial of GLX-100 will be presented at the 2025 American Urological Association (AUA) Annual Meeting by Dr. Jeffrey Proctor. This data represents an important milestone in the development of GLX-100.

March 2025:
GLX-100 Spotlighted in UroToday for Innovation in Interstitial Cystitis

UroToday featured Glycologix’ GLX-100 program, spotlighting the scientific rationale, preclinical results, and clinical progress.

January 2025:
Glycologix’ GLX-100 Pre-Clinical Research Published in PLOS One

Glycologix’ preclinical research on GLX-100 has been published in PLOS One. The manuscript highlights the development and testing of a crosslinked chondroitin sulfate polymer designed to restore the bladder’s protective GAG layer; supporting its’ therapeutic potential in IC.

December 2024:
GLX-100 Phase 1b Clinical Trial Concludes; Preliminary Results Pave Way for Phase 2b Study

Glycologix has successfully completed a multi-center, Phase 1b clinical trial of GLX-100 in Australia. Early results show promising safety and efficacy signals, paving the way for advancement to a Phase 2b clinical study.

May 2024:
Glycologix Third US Patent Granted: US 11,975,019

February 2024:
Glycologix Second US Patent Granted: US 11,911,411

October 2023:
Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

March 2023:
Glycologix Selected for AUA Innovation Nexus Showcase

Glycologix is one of only 10 companies selected to present at the prestigious AUA Innovation Nexus. CEO Dan Deardorf presented Glycologix’ GLX-100 development program for Interstitial Cystitis.

October 2022:
Glycologix’ CSO Presents on Glycologix Platform at Biointerface-2022

Glycologix’ Chief Science Officer, Dr. Thomas Jozefiak, presented on the design of Glycologix biopolymers and preclinical results in animal models of permeable bladder at the Surfaces in Biomaterials Foundation annual conference, Biointerface-2022 in Portland Oregon.

May 2021:
Glycologix receives notice of first issued US patent: US 11,090,327

February 2021:
Glycologix Biopolymer Discovery Published in Pharmacology Research & Perspectives.

Glycologix’ first scientific publication, detailing the design of Glycologix’ Biopolymers and their effectiveness in reducing bladder permeability in two different rodent models of permeable bladder was published in the British Pharmacological Society’s Journal, Pharmacology Research & Perspectives.

January 2021:
Dan Deardorf joins Glycologix as President and Chief Executive Officer

Dan brings 25+ years of biopharma experience developing and commercializing products across multiple technology platforms, including locally delivered biomaterial therapies.

October 2020:
Glycologix receives notice of issued Australian patent

July 2020:
Rich Heidebrecht, PhD, joins Glycologix as Vice President of Research and Development

Rich brings two decades of diverse drug development experience to Glycologix, specializing in bringing discoveries from concept to the clinic.

June 2020:
Glycologix awarded $2M NIH SBIR Phase II grant

June 2018:
Glycologix awarded $287K NIH SBIR Phase I grant

March 2018:
Lead patent published under Patent Cooperation Treaty (PCT), WO2018053276

March 2016:
Glycologix founded

Glycologix, LLC was founded by inventor Dr. Thomas H. Jozefiak, and serial entrepreneur and angel investor, George Adaniya. Dr. Jozefiak serves as Chief Scientific Officer and Mr. Adaniya is Chief Executive Officer. The company was founded to develop proteoglycan mimic biopolymers for use in regenerative medicine applications. Glycologix is headquartered at North Shore Innoventures Beverly, MA.